HK1035534A1 - Macrocyclic analogs and methods of their use and preparation - Google Patents

Macrocyclic analogs and methods of their use and preparation

Info

Publication number
HK1035534A1
HK1035534A1 HK01106122.7A HK01106122A HK1035534A1 HK 1035534 A1 HK1035534 A1 HK 1035534A1 HK 01106122 A HK01106122 A HK 01106122A HK 1035534 A1 HK1035534 A1 HK 1035534A1
Authority
HK
Hong Kong
Prior art keywords
preparation
methods
macrocyclic analogs
analogs
macrocyclic
Prior art date
Application number
HK01106122.7A
Other languages
English (en)
Inventor
Bruce A Littlefield
Monica Palme
Boris M Seletsky
Murray J Towle
Melvin J Yu
Wanjun Zheng
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1035534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of HK1035534A1 publication Critical patent/HK1035534A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HK01106122.7A 1998-06-17 2001-08-29 Macrocyclic analogs and methods of their use and preparation HK1035534A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (1)

Publication Number Publication Date
HK1035534A1 true HK1035534A1 (en) 2001-11-30

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106122.7A HK1035534A1 (en) 1998-06-17 2001-08-29 Macrocyclic analogs and methods of their use and preparation

Country Status (24)

Country Link
US (4) US6214865B1 (de)
EP (4) EP1087960B1 (de)
JP (1) JP4454151B2 (de)
KR (1) KR100798600B1 (de)
CN (1) CN1216051C (de)
AT (1) ATE502932T1 (de)
AU (1) AU762998B2 (de)
BE (1) BE2011C028I2 (de)
BR (1) BRPI9911326B8 (de)
CA (3) CA2755266C (de)
CY (2) CY1111516T1 (de)
DE (2) DE69943296D1 (de)
DK (1) DK1087960T3 (de)
FR (1) FR11C0038I2 (de)
HK (1) HK1035534A1 (de)
HU (1) HU227912B1 (de)
IL (1) IL139960A0 (de)
LU (1) LU91854I2 (de)
NO (5) NO328280B1 (de)
NZ (1) NZ508597A (de)
PT (1) PT1087960E (de)
RU (1) RU2245335C2 (de)
WO (1) WO1999065894A1 (de)
ZA (1) ZA200007159B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69943296D1 (de) 1998-06-17 2011-05-05 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1531846A4 (de) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Konjugate aus ligand, linker und zytotoxischem agens sowie verwandte zusammensetzungen und verwendungsverfahren
PL219737B1 (pl) 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
EP1644008B1 (de) * 2003-05-29 2011-12-21 Abbott Laboratories Kontinuierliches dosierschema mit abt-751
EP1653953A4 (de) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd Verfahren und vorrichtungen für die arzneimittelabgabe
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
USRE46965E1 (en) * 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
CA2701534C (en) 2007-10-03 2017-02-21 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
RU2517167C2 (ru) * 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
EP2415470B1 (de) 2009-03-30 2016-07-06 Eisai R&D Management Co., Ltd. Liposomenzusammensetzung
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
US8765974B2 (en) * 2009-04-14 2014-07-01 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
SG10201500552PA (en) 2010-01-26 2015-03-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
JP2014509515A (ja) 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
AU2012363334B2 (en) * 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
WO2013142999A1 (en) * 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CA2892780A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
WO2014183211A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
JP6404242B2 (ja) 2013-06-26 2018-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
CN105431438A (zh) * 2013-07-03 2016-03-23 阿方拉研究股份有限公司 用于制备软海绵素b 的大环c1-酮基类似物的合成方法和可用于其中的中间体、包括含有-so2-(对甲苯基)基团的中间体
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
EP3066102B1 (de) 2013-11-04 2020-02-26 Eisai R&D Management Co., Ltd. Makrozyklierungsreaktionen und zwischenprodukte zur synthese von analoga von halichondrin b
CA2931788C (en) 2013-12-06 2022-05-24 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) * 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
JP2017516802A (ja) * 2014-05-28 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリンの使用
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
EP3191479B1 (de) * 2014-09-09 2020-04-08 Cipla Limited Verfahren zur herstellung von macrocyclischen keton-analoga von halichondrin b oder ihrer pharmazeutisch geeigneten salze und dessen intermediate
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
RU2737216C2 (ru) 2015-03-04 2020-11-26 Мерк Шарп Энд Дохме Корп. Комбинация антагониста pd-1 и эрибулина для лечения рака
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN117024469A (zh) * 2015-05-07 2023-11-10 卫材R&D管理有限公司 可用于合成软海绵素大环内酯的大环化反应以及中间体和其他片段
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
EP3413887B1 (de) * 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Zwischenprodukte bei der synthese von eribulin und zugehörige syntheseverfahren
US20190111022A1 (en) 2016-04-28 2019-04-18 Eisai R&D Management Co., Ltd. Method for Inhibiting Tumor Growth
JP2019521969A (ja) * 2016-05-26 2019-08-08 ドクター レディズ ラボラトリーズ リミテッド エリブリン及びその中間体の製造方法
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
US20190263927A1 (en) 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US10836776B2 (en) 2016-11-23 2020-11-17 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN110139866B (zh) * 2017-01-02 2022-05-17 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体以及制备其的方法
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2018187331A1 (en) 2017-04-05 2018-10-11 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
IL307273A (en) 2017-07-06 2023-11-01 Harvard College Synthesis of the Lichondrins
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
EP3712141B1 (de) * 2017-11-09 2023-07-12 Yonsung Fine Chemical Co., Ltd. Zwischenprodukt zur herstellung von eribulinmesylat und verfahren zu seiner herstellung
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en) 2017-11-21 2019-05-31 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
CN111868044A (zh) 2018-01-03 2020-10-30 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
EP3823973A4 (de) * 2018-07-20 2022-09-21 Dr. Reddy's Laboratories Limited Reinigungsverfahren zur herstellung von eribulin und zwischenprodukten davon
EP3864011A4 (de) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Verfahren zur herstellung von eribulin und zwischenprodukten davon
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US20220333139A1 (en) 2019-06-21 2022-10-20 Council Of Scientific And Industrial Research A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
EP4055053A1 (de) 2019-11-07 2022-09-14 Eisai R&D Management Co., Ltd. Anti-mesothelin-antikörper-arzneimittel-konjugate und verfahren zur verwendung
CN113135876A (zh) * 2020-01-16 2021-07-20 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
EP4094779A4 (de) * 2020-01-22 2023-11-22 Shanghai Senhui Medicine Co., Ltd. Wirkstoffkonjugat von eribulinderivat, verfahren zu seiner herstellung und seine verwendung in der medizin
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
CN117460540A (zh) * 2021-07-22 2024-01-26 上海森辉医药有限公司 艾日布林衍生物的药物偶联物
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE69943296D1 (de) * 1998-06-17 2011-05-05 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
USRE46965E1 (en) 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
CA2701534C (en) 2007-10-03 2017-02-21 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
MX2010005340A (es) 2007-11-16 2010-12-21 Eisai R&D Man Co Ltd Novedoso intermediario para la sintesis del analogo b de halicondrina y novedosa reaccion de desulfonilacion usada para el intermediario.
RU2517167C2 (ru) 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
SG10201500552PA (en) 2010-01-26 2015-03-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Also Published As

Publication number Publication date
CA2335300A1 (en) 1999-12-23
NO20093217L (no) 2001-02-15
DE122011100031I1 (de) 2011-12-15
AU4573999A (en) 2000-01-05
BE2011C028I2 (en) 2018-08-24
DE69943296D1 (de) 2011-05-05
US6469182B1 (en) 2002-10-22
EP1087960B1 (de) 2011-03-23
BR9911326B1 (pt) 2015-01-06
EP1087960A1 (de) 2001-04-04
NO20006316D0 (no) 2000-12-12
HUP0103357A3 (en) 2002-10-28
KR100798600B1 (ko) 2008-01-28
EP2272839B1 (de) 2012-08-22
NO331183B1 (no) 2011-10-24
EP2272839A1 (de) 2011-01-12
CY2011010I1 (el) 2014-04-09
NO328280B1 (no) 2010-01-25
EP2272840B1 (de) 2012-08-22
IL139960A0 (en) 2002-02-10
FR11C0038I2 (fr) 2013-01-11
DK1087960T3 (da) 2011-06-14
PT1087960E (pt) 2011-06-17
AU762998C (en) 2000-01-05
HUP0103357A2 (hu) 2002-01-28
EP1087960A4 (de) 2004-12-01
NO2022019I1 (no) 2022-06-03
CA2755266C (en) 2014-08-12
US6365759B1 (en) 2002-04-02
CA2632433A1 (en) 1999-12-23
CA2755266A1 (en) 1999-12-23
CN1216051C (zh) 2005-08-24
ZA200007159B (en) 2001-12-04
CY2011010I2 (el) 2014-04-09
CY1111516T1 (el) 2014-04-09
NO2011018I1 (no) 2011-09-26
US20110172446A1 (en) 2011-07-14
US8148554B2 (en) 2012-04-03
RU2245335C2 (ru) 2005-01-27
US6214865B1 (en) 2001-04-10
LU91854I2 (fr) 2011-10-17
ATE502932T1 (de) 2011-04-15
HU227912B1 (en) 2012-05-29
CA2632433C (en) 2012-02-07
NO2011026I2 (no) 2012-06-11
WO1999065894A1 (en) 1999-12-23
AU762998B2 (en) 2003-07-10
BR9911326A (pt) 2001-04-03
NZ508597A (en) 2004-01-30
EP2272840A1 (de) 2011-01-12
EP2277873A1 (de) 2011-01-26
EP2277873B1 (de) 2012-05-30
JP4454151B2 (ja) 2010-04-21
CA2335300C (en) 2008-10-07
KR20010083050A (ko) 2001-08-31
FR11C0038I1 (fr) 2011-10-14
CN1312804A (zh) 2001-09-12
NO20006316L (no) 2001-02-15
JP2002518384A (ja) 2002-06-25
BRPI9911326B8 (pt) 2021-05-25
NO2011026I1 (no) 2012-01-09

Similar Documents

Publication Publication Date Title
HK1035534A1 (en) Macrocyclic analogs and methods of their use and preparation
DE69925133D1 (de) Pyrrolobenzodiazepine
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
SG47559A1 (en) 7-(substituted)-9-[(substituted glycl) amido]-6-demethyl-6-deoxytetracyclines
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
EP0781561A4 (de) Eine neuartige medizinische verwendung eines 5ht 3?-antagonisten
EP1274443A4 (de) Mizellen
NZ241254A (en) 2,8-dioxabicyclo(3.2.1)octane-3,4,5-tricarboxylic acid derivatives; their preparation, intermediates therefor and medicaments
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
GR850799B (de)
AU2001249684A1 (en) Nasal administration of agents for the treatment of gastroparesis
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
EP1073447A4 (de) N1 modifizierte glycopeptide
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
HUT75124A (en) Use of bicyclolactam derivatives for producing pharmaceutical compositions having anxiolytic activity
HK1067948A1 (en) Antitumor indolopyprolocarbazole derivative
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190615